BioPhenoMA
BioPhenoMA develops ultrasensitive protein detection technology for oncology and immunology research, enabling quantification of trace proteins without specialized equipment.
Private Company
Funding information not available
AI Company Overview
BioPhenoMA develops ultrasensitive protein detection technology for oncology and immunology research, enabling quantification of trace proteins without specialized equipment.
Technology Platform
TN-cyclon™ (improved enzyme cycling method) enables ultrasensitive protein detection (LOD <1 pg/mL) without specialized equipment by combining enzyme cycling with proprietary pretreatment and fractionation techniques that preserve biological structure.
Opportunities
Risk Factors
Competitive Landscape
Competes with Olink, SomaLogic, and mass spectrometry-based proteomics platforms; differentiates through extreme sensitivity, equipment simplicity, and preservation of biological context during protein quantification.